Retatrutide (LY3437943) is an investigational once-weekly injectable medicine being studied for obesity and metabolic diseases. Because it is not FDA-approved (as of this writing), the main legitimate way to access it in the US is through a registered clinical trial.
This guide is written as a practical Q&A so you can go from “I’m curious” → “I’m screened” with fewer surprises.
Educational only, not medical advice. Clinical trials have benefits and risks. Always discuss participation with your clinician—especially if you have diabetes, kidney disease, gallbladder disease, pancreatitis history, severe GERD, a history of eating disorders, or pregnancy plans.
Short answer
If you want to join a retatrutide trial in the US:
- Search reputable trial registries (start with ClinicalTrials.gov) for “retatrutide” and your state.
- Open a study record and confirm:
- Recruitment status is actually recruiting or not yet recruiting (not “active, not recruiting”)
- There is a real US site location and a study contact
- The sponsor is credible (e.g., a major academic center or the manufacturer / experienced research network)
- Pre-screen yourself using the “Eligibility Criteria” section (age, BMI, conditions, medications).
- Contact the site (phone/email) and ask for a screening call.
- If you’re potentially eligible, expect:
- Informed consent (you should get time to read it)
- A screening period with labs, vitals, medication review
- Randomization (you may get placebo)
- Regular clinic visits and/or remote check-ins over months
- Pay should be $0 for the study drug and required research tests. You may receive travel reimbursement or modest compensation for time.
- Avoid scams: real trials don’t sell you the drug, don’t ask for wire transfers, and don’t recruit via “DM me for retatrutide” posts.
Quick checklist (printable)
Use this before you invest time:
- I understand retatrutide is investigational; I may receive placebo.
- I found the trial on ClinicalTrials.gov (or a major academic/health system page that links to an NCT number).
- The study shows Recruiting / Not yet recruiting and has a US location near me.
- I roughly match key eligibility: age range, BMI range, and condition (obesity, T2D, etc.).
- I can commit to the visit schedule (often frequent early visits + ongoing check-ins).
- I’m comfortable with requirements (injections, labs, contraception rules, stopping certain meds).
- I have a plan for what happens after the trial (no guarantee of continued access).
- I can identify and avoid red flags (upfront fees, “guaranteed access,” no consent process).
Q&A: finding and joining a retatrutide trial
Q1) What is retatrutide, and why does trial access work differently than prescriptions?
Retatrutide is not a prescription product in the US yet. It is being evaluated in clinical trials, so:
- You generally cannot get it from a retail pharmacy.
- You should not expect insurance coverage for it.
- Legitimate access is typically through IRB-approved research with oversight, a protocol, safety monitoring, and informed consent.
Retatrutide is often described as a triple receptor agonist (GIP + GLP-1 + glucagon receptors). That mechanism is one reason it’s being studied for large weight loss and metabolic effects—but it’s also why careful safety evaluation matters.
Q2) Where do I look for legitimate US retatrutide trials?
Start with ClinicalTrials.gov, the US registry of federally and privately supported clinical studies.
Best places to search:
- ClinicalTrials.gov (primary): search “retatrutide” and filter by location.
- Major academic medical centers (sometimes have a “research studies” directory).
- NIH resources explaining how to find trials and what to consider.
Avoid relying on:
- Random “trial matching” ads that hide the study name/NCT number
- Social media posts offering to “ship retatrutide”
- Sites that won’t tell you the sponsor, location, or consent process
Q3) How do I search ClinicalTrials.gov effectively?
- Search: retatrutide (also try LY3437943).
- Filter by:
- Location: United States + your state/city radius
- Recruitment: Recruiting / Not yet recruiting
- Age group: Adult (if applicable)
- Open each study record and scan:
- Purpose (what condition and outcomes?)
- Interventions (retatrutide vs placebo or vs active comparator)
- Study design (randomized? blinded? duration?)
- Eligibility Criteria (BMI, A1c, comorbidities, meds)
- Contacts and Locations (site phone/email)
- NCT number (unique identifier)
A practical trick: copy the NCT number and search it in Google plus your state or the hospital name; many sites list local recruiting details on their own pages.
Q4) What does “Recruiting,” “Not yet recruiting,” and “Active, not recruiting” actually mean?
- Not yet recruiting: sites may be setting up. You can often join a waitlist.
- Recruiting: the site is actively screening/enrolling.
- Active, not recruiting: the study is ongoing but not enrolling new participants.
- Completed/Terminated/Withdrawn: not enrolling.
Even if a record says “Recruiting,” individual sites can be full. That’s normal.
Q5) What are common eligibility requirements (in plain English)?
Each protocol is different, but retatrutide trials for obesity/metabolic disease often include criteria like:
Common inclusions (examples, not promises):
- Age: often adults (e.g., 18+; sometimes capped at a higher age)
- Body size: BMI thresholds (e.g., obesity range; sometimes overweight with comorbidities)
- Medical condition: obesity, type 2 diabetes, obstructive sleep apnea, osteoarthritis, etc.
- Ability to follow the protocol (visits, injections, diaries)
Common exclusions / “might disqualify you” topics:
- Pregnancy or planned pregnancy; contraception requirements may apply
- Certain endocrine conditions (e.g., uncontrolled thyroid disease)
- Significant GI disease (depending on protocol)
- Some histories of pancreatitis/gallbladder disease (protocol-dependent)
- Recent use of certain weight-loss meds or other incretin drugs (protocol-dependent)
- Unstable cardiovascular disease or very high-risk conditions (protocol-dependent)
- Recent bariatric surgery (timing and type may matter)
The key point: eligibility is precise and protocol-driven, not “doctor’s discretion.” You may be healthy enough for the drug clinically, but still ineligible because of study design.
Q6) Can I join if I’m already on Wegovy, Ozempic, Mounjaro, or Zepbound?
Maybe, but often not immediately.
Many trials restrict or require a washout period from GLP-1/GIP medications because they can confound results. Some protocols allow stable background therapy in diabetes studies; others prohibit it.
What to ask the study team:
- “Do you allow prior GLP-1/GIP use?”
- “If yes, what washout period is required?”
- “Do you require documentation from my prescribing clinician?”
Do not stop prescribed medication without talking to your clinician.
Q7) What is the typical time commitment?
Time commitment depends on the phase and purpose of the study, but many obesity/metabolic drug trials resemble:
- Screening period: 2–8 weeks (varies)
- Treatment period: commonly months (sometimes ~1 year or longer)
- Follow-up: additional weeks/months after last dose
Visit frequency is often highest early:
- Early dose escalation phase: visits every 1–4 weeks
- Later maintenance phase: visits may spread out (e.g., every 4–12 weeks)
Expect some combination of:
- In-clinic visits (vitals, weight, labs)
- Phone/video check-ins
- App-based symptom logs
- Study drug training (how to inject)
Reality check: If a trial is 68+ weeks, you’re making a long-term commitment. The best predictor of success is whether the logistics fit your actual life.
Q8) What does participation usually cost?
For legitimate US drug trials:
- The study drug is typically provided at no cost.
- Research-required visits/tests are typically covered by the sponsor.
- You may receive travel reimbursement (mileage, parking) and/or modest compensation for time.
You might still encounter costs like:
- Time off work
- Childcare
- Transportation beyond what the study reimburses
- Usual medical care unrelated to the study
Important: the consent form should explain what is paid by the study vs billed to insurance. If anything is unclear, ask for a plain-language breakdown.
Q9) Do I get paid? How much?
Some studies compensate participants; some don’t. When compensation is offered, it is usually meant to offset time and inconvenience—not to be “income.”
Typical patterns:
- Small payments per completed visit
- Reimbursement for travel/parking
- Higher compensation for more intensive procedures (e.g., imaging, biopsies)
Red flag: unusually high pay that feels like it’s designed to override your judgment, especially if combined with vague details.
Q10) Will I definitely receive retatrutide?
No.
Many trials are randomized and blinded, which means:
- You might receive placebo.
- You might receive a different dose than the highest dose.
- In some designs, you might receive an active comparator (another medication) or standard-of-care.
Ask:
- “What are the chances of placebo?”
- “Is there an open-label extension after the main trial?”
Even in an extension, continued access is not guaranteed and depends on the study design, safety, and sponsor decisions.
Q11) What happens at the first contact / pre-screening call?
A typical first call is 10–20 minutes. The coordinator may ask:
- Age, height/weight (BMI estimate)
- Diagnosis history (T2D, sleep apnea, etc.)
- Medication list (especially GLP-1s, insulin, steroids)
- Relevant past history (pancreatitis, gallstones, thyroid cancer in family, etc.)
- Whether you can attend visits and follow study requirements
Tip: have ready:
- Current medication list (name + dose)
- A1c if you know it (for diabetes studies)
- Approximate weight history
- Your schedule constraints (work hours, travel)
Q12) What is informed consent, and what should I expect?
Informed consent is a process, not a signature. You should receive a consent document describing the study’s purpose, procedures, potential risks/benefits, alternatives, confidentiality, and contact information.
What “good” consent feels like:
- You are not rushed.
- You’re encouraged to ask questions.
- You can take the document home (or review electronically) before signing.
- The team explains what is experimental vs standard care.
If you feel pressured—pause.
Q13) What questions should I ask the study team before signing?
Bring a list. Here are high-yield questions that protect you:
About the study drug and design
- “Is this placebo-controlled? What’s the randomization ratio?”
- “How long is the treatment period and total study duration?”
- “What dose escalation schedule is used?”
- “What happens if I have side effects—can my dose be held or reduced?”
About visits and procedures
- “How many in-person visits? How long does each visit take?”
- “Which procedures are required (blood draws, ECG, imaging)?”
- “Are there remote visits, or can any visits be at a closer site?”
About costs and compensation
- “What does the study pay for? What might be billed to my insurance?”
- “Do you reimburse travel/parking?”
- “Is compensation prorated if I withdraw?”
About safety and your rights
- “What side effects have you seen in similar trials?”
- “Who do I call after hours if I have symptoms?”
- “If new risks are discovered, how will I be informed?”
- “Can I leave the study at any time? What happens if I do?”
About after the trial
- “Is there an open-label extension?”
- “Will I have any access to retatrutide after the study ends?”
- “What follow-up care do you provide when the trial ends?”
Q14) What are common procedures in metabolic/weight-loss drug trials?
While each protocol differs, common elements include:
- Medical history review + physical exam
- Vitals (blood pressure, heart rate)
- Weight, waist circumference
- Blood tests (glucose, A1c, lipids, liver enzymes, kidney function)
- Pregnancy tests if applicable
- ECG (heart rhythm)
- Questionnaires (appetite, quality of life)
- Diet/exercise counseling standardization (sometimes)
You may also see:
- Body composition scans (DXA)
- Sleep studies (if sleep apnea trials)
- Imaging of joints (if osteoarthritis trials)
Q15) What side effects should I be aware of when considering enrollment?
You’ll get the most accurate info from the consent form and study team, but for incretin-based medicines in general, common issues may include:
- GI symptoms: nausea, vomiting, diarrhea, constipation
- Appetite changes
- Injection-site reactions
- Changes in heart rate (protocol-dependent monitoring)
There can be rarer but more serious risks discussed in consent depending on the molecule and population studied.
If you have a history of severe GI disease, gallbladder disease, pancreatitis, kidney issues, or are on complex diabetes regimens, ask specifically how the trial monitors and manages those risks.
Q16) Can my primary care doctor or endocrinologist help with trial enrollment?
Yes—often in two ways:
- Medical records: trials may require documentation (diagnoses, labs, imaging).
- Clinical guidance: your clinician can help you weigh risks, and help manage medications that might interact with trial requirements.
A helpful approach: ask your clinician to provide a concise summary of your relevant history and current meds to the study site.
Q17) What if there are no retatrutide trials near me?
Options:
- Waitlist: contact sites that are “not yet recruiting.”
- Widen your radius: some people travel for trials, but consider the true burden.
- Look at related investigational options: other pipeline obesity drugs may have more local recruiting.
- Consider FDA-approved alternatives now: semaglutide/tirzepatide may be accessible with insurance, appeals, or patient assistance (depending on indication).
Do not buy “retatrutide” online claiming it is the real drug—those products are frequently misbranded or counterfeit.
The step-by-step enrollment path (what it usually looks like)
Below is a typical flow; your trial may differ.
Step 1: Identify 3–10 candidate trials
Make a shortlist so you’re not stuck if one site is full.
For each study, record:
- NCT number
- Sponsor
- Condition (obesity, T2D, OSA, etc.)
- Distance to site
- Recruitment status
- Contact details
Step 2: Pre-check eligibility fast
Before calling, check:
- Age range
- BMI range
- Key exclusions (recent meds, surgeries, unstable conditions)
If you’re unsure, call anyway—sites do quick pre-screens all day.
Step 3: Call/email the site contact
A simple script:
- “Hi—I’m calling about NCT____. I’m interested in screening. Could I do a pre-screen call with the coordinator?”
If no response, follow up once a week for 2–3 weeks. Research sites are busy.
Step 4: Screening visit(s)
If you pass pre-screen:
- You’ll review and sign informed consent.
- You’ll complete baseline assessments.
- You may do labs and be asked to stop certain supplements/meds (only under medical guidance).
Step 5: Randomization + first dose
If screening labs/criteria are met, you are randomized and trained.
Step 6: Ongoing visits and monitoring
You’ll likely track symptoms, side effects, and possibly diet/activity.
Step 7: End-of-study and follow-up
There is usually:
- A final evaluation
- Safety follow-up period
- Discussion of next steps (including that you may not keep the study drug)
Red flags: how to spot scams and bad-faith “trial” offers
Retatrutide interest is high. That attracts scams.
Major red flags (walk away)
- They sell you retatrutide or ask you to pay for “enrollment.”
- They ask for wire transfer, crypto, gift cards, or “application fee.”
- They claim you’ll get “guaranteed retatrutide” with no mention of placebo.
- No informed consent process, or they won’t let you read consent before arriving.
- No NCT number, no verifiable sponsor, no real clinic address.
- They want to recruit you exclusively via DMs and won’t provide official contact details.
Yellow flags (slow down and verify)
- The recruiter can’t explain the study design or visit schedule.
- Compensation is unusually high and details are vague.
- The site is far away but insists frequent in-person visits without travel support.
How to verify legitimacy quickly
- Confirm the trial exists on ClinicalTrials.gov and matches the name/intervention.
- Call the hospital/clinic main number (not just the recruiter’s cell) and ask to be transferred to the research department.
- Ask for the IRB name and whether the study is IRB-approved at that site.
Special situations people ask about
“I have type 2 diabetes—are there extra considerations?”
Yes. Diabetes trials can include:
- More frequent glucose monitoring
- Medication adjustments (especially insulin or sulfonylureas)
- Higher attention to hypoglycemia risk depending on background therapy
Ask exactly what glucose monitoring is required and who manages medication changes.
“I’m planning pregnancy (or could become pregnant). Can I participate?”
Many metabolic drug trials require:
- Negative pregnancy testing
- Reliable contraception
- Restrictions on becoming pregnant during the study and for a period after
If pregnancy is possible for you, ask for the exact contraception and timing requirements.
“Can I do the trial remotely?”
Some elements can be remote (televisits, symptom logs), but drug trials usually require in-person visits for labs and assessments—especially early.
A realistic expectations section (so you’re not disappointed)
You may be screened out even if you seem like a good candidate
Screen failures are common and not personal. Reasons include lab cutoffs, medication conflicts, or the site being full.
You may not lose much weight (even if the drug is strong)
Reasons include placebo assignment, dose differences, individual response variability, or protocol requirements.
You might have to stop other weight-loss meds
Some protocols require it; that trade-off can be meaningful.
There is no guarantee of continued access after the trial
Plan what you will do next (approved meds, lifestyle program, bariatric consult, etc.).
Template: email to a study site
Subject: Interest in screening for retatrutide study (NCT____)
Hello,
I’m interested in screening for the study NCT____ listed on ClinicalTrials.gov. I’m an adult in [city/state] and believe I may meet basic eligibility.
Could we schedule a brief pre-screen phone call? If helpful, I can share my current medications and recent relevant labs.
Thank you,
[Name]
[Phone]
References and official resources
- FDA (Aug 2023). Informed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors. FDA Guidance Document page: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent
- NIH (updated Apr 2025). Finding a Clinical Trial. Includes explanation of what ClinicalTrials.gov contains and cautions that listings are not government endorsements: https://www.nih.gov/health-information/nih-clinical-research-trials-you/finding-clinical-trial
- ClinicalTrials.gov (NLM/NIH). Study registry and search portal: https://clinicaltrials.gov/
- ClinicalTrials.gov (NLM/NIH). How to Search / Find Studies (official how-to entry point): https://clinicaltrials.gov/find-studies/how-to-search
- NEJM (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. (Background efficacy/safety context; not a “how to enroll” resource): https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Appendix: mini glossary
- IRB (Institutional Review Board): Independent ethics committee that reviews research to protect participants.
- Informed consent: The process of learning about the study and voluntarily agreeing to participate.
- Randomized: Assignment to treatment groups is by chance.
- Blinded: You (and sometimes the study team) may not know which group you’re in.
- Placebo-controlled: Some participants receive an inactive injection so researchers can compare outcomes.
- NCT number: Unique identifier for a ClinicalTrials.gov study record.